Titre :

Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Auteur(s) :

Yeoh, S. A. [Auteur]
Gianfrancesco, M. [Auteur]
Lawson-Tovey, S. [Auteur]
Hyrich, K. L. [Auteur]
Strangfeld, A. [Auteur]
Gossec, Laure [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Carmona, L. [Auteur]
Mateus, E. F. [Auteur]
Schäfer, M. [Auteur]
Richez, Christophe [Auteur]
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Holmqvist, M. [Auteur]
Scirè, C. A. [Auteur]
Lorenz, H. M. [Auteur]
Voll, R. E. [Auteur]
Hasseli, R. [Auteur]
Jayatilleke, A. [Auteur]
Hsu, T. Y. [Auteur]
D'silva, K. M. [Auteur]
Pimentel-Quiroz, V. R. [Auteur]
Vasquez Del Mercado, M. [Auteur]
Shinjo, S. K. [Auteur]
Neto, E. T. D. R. [Auteur]
Junior, L. F. D. R. [Auteur]
De Oliveira E Silva Montandon, A. C. [Auteur]
Pons-Estel, G. J. [Auteur]
Ornella, S. [Auteur]
D'angelo Exeni, M. E. [Auteur]
Velozo, E. [Auteur]
Jordan, P. [Auteur]
Sirotich, E. [Auteur]
Hausmann, J. S. [Auteur]
Liew, J. W. [Auteur]
Jacobsohn, L. [Auteur]
Gore-Massy, M. [Auteur]
Sufka, P. [Auteur]
Grainger, R. [Auteur]
Bhana, S. [Auteur]
Wallace, Z. [Auteur]
Robinson, P. C. [Auteur]
Yazdany, J. [Auteur]
Machado, P. M. [Auteur]

Titre de la revue :

RMD Open

Nom court de la revue :

RMD Open

Numéro :

8

Date de publication :

2022-09-15

ISSN :

2056-5933

Mot(s)-clé(s) en anglais :

polymyositis
dermatomyositis
COVID-19
outcome assessment
health care
epidemiology

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM). Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with ...
Lire la suite >Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM). Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death. Results Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65–1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51–0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively). Conclusions This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with IIM.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T00:38:04Z
2024-03-20T09:05:18Z